← All organizations
Highest phase reached
Phase 3
Timeline
2000s
- Dec 1, 2009
Shanghai Henlius Biotech— Founded
2020s
- Aug 29, 2025
denosumab— Marketing Organization
Drugs by trial phase (59 distinct, 110 trials)
Phase 3 (34 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (12 own, 0 via acquisition)
Indications
Studied for
- Arthritis
- Arthritis, Rheumatoid
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Disease Progression
- Esophageal Squamous Cell Carcinoma
- Head and Neck Neoplasms
- Immune System Diseases
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Neoplasms
- Psoriasis
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Uterine Cervical Neoplasms
Marketed drugs (2)
Recent trials (50)
- NCT07294508Lead sponsorPhase 2/Phase 3Jan 25, 2026
- NCT07269782Lead sponsorPhase 2Jan 20, 2026
- NCT07253142Lead sponsorPhase 2Jan 14, 2026
- NCT07301229Lead sponsorPhase 2Dec 29, 2025
- NCT07274813Lead sponsorEarly Phase 1Nov 28, 2025
- NCT07176650Lead sponsorPhase 1Oct 31, 2025
- NCT07160335Lead sponsorPhase 1Sep 26, 2025
- NCT07106892Lead sponsorPhase 2Sep 15, 2025
- NCT07115485Lead sponsorPhase 2Sep 15, 2025
- NCT07106892OfficialPhase 2Sep 15, 2025
- NCT07038382Lead sponsorPhase 2Aug 5, 2025
- NCT06907615Lead sponsorPhase 2Jun 9, 2025
- NCT06980454Lead sponsorPhase 1Jun 4, 2025
- NCT06895512Lead sponsorPhase 3Apr 30, 2025
- NCT06841185Lead sponsorPhase 3Apr 30, 2025
Details
- Founded
- Shanghai, CN Dec 1, 2009
- Last known activity
- Jan 25, 2026